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AbstrACt
Introduction Current treatment guidelines for European 
Lyme neuroborreliosis (LNB) recommend cephalosporins, 
penicillin or doxycycline for 14–28 days but evidence for 
optimal treatment length is poor. Treatment lengths in 
clinical practice tend to exceed the recommendations. 
Most patients experience a rapid improvement of 
symptoms and neurological findings within days of 
treatment, but some report long-term complaints. The 
underlying mechanisms of remaining complaints are 
debated, and theories as ongoing chronic infection with 
Borrelia burgdorferi, dysregulated immune responses, 
genetic predisposition, coinfection with multiple tick-
borne pathogens, structural changes in CNS and personal 
traits have been suggested. The main purpose of our 
trial is to address the hypothesis of improved outcome 
after long-term antibiotic treatment of LNB, by comparing 
efficacy of treatment with 2 and 6 weeks courses of 
doxycycline.
Methods and analysis The trial has a multicentre, 
non-inferiority, double-blinded design. One hundred 
and twenty patients diagnosed with LNB according to 
European Federation of Neurological Societies (EFNS)
guidelines will be randomised to 6 or 2 weeks treatment 
with oral doxycycline. The patients will be followed for 
12 months. The primary endpoint is improvement on a 
composite clinical score (CCS) from baseline to 6 months 
after inclusion. Secondary endpoints are improvements 
in the CCS 12 months after inclusion, fatigue scored on 
Fatigue Severity Scale, subjective symptoms on the Patient 
Health Questionnaire-15 scale, health-related quality of 
life scored on RAND 36-item short form health survey and 
safety as measured by side effects of the two treatment 
arms. Blood and cerebrospinal fluid (CSF) are collected 
from inclusion and throughout the follow-up and a biobank 
will be established. The study started including patients in 
November 2015 and will continue throughout December 
2019.
Ethics and dissemination The study is approved by the 
Norwegian regional committees for medical and health 
research ethics and the Norwegian Medicines Agency. 
Data from the study will be published in peer-reviewed 
medical journals.
trial registration number 2015-001481-25
IntroduCtIon
European Lyme neuroborreliosis (LNB) is 
caused by the tick-borne spirochete Borrelia 
burgdorferi (Bb). LNB can manifest weeks or 
months after a tick bite that only half of the 
patients remember. The most common clinical 
manifestations are subacute painful radiculitis 
and cranial neuropathy (most often the facial 
nerve). More rare manifestations are myelitis, 
encephalitis and peripheral neuropathies.
Patients diagnosed with LNB should be 
treated with antibiotics as early as possible to 
relieve symptoms and prevent sequelae.1–3 
Most patients experience a rapid improvement 
within days of treatment, but some report 
long-term complaints.4 The most common 
long-term complaints are fatigue, pain, concen-
tration and memory problems. Some patients 
may also have neurological sequela such as 
sensory disturbances, unsteadiness/vertigo, 
facial paresis and other paresis.5 The under-
lying mechanisms of remaining complaints 
are debated. Theories suggested are ongoing 
chronic Bb infection, dysregulated immune 
responses, genetic predisposition, coinfection 
with multiple tick-borne pathogens, structural 
changes in CNS and personal traits.
Standard treatment for LNB is intravenous 
ceftriaxone or penicillin, or oral doxycycline 
strengths and limitations of this study
 ► The trial has a double-blinded design.
 ► The inclusion criteria for Lyme neuroborreliosis are 
according to the EFNS guidelines.
 ► The endpoints of the trial are well-defined.
 ► The follow-up period of the included patients is long 
with registered symptoms, signs and potential side 
effects.
 ► A weakness of the study is that the primary scoring 















pen: first published as 10.1136/bm




2 Solheim AM, et al. BMJ Open 2019;9:e027083. doi:10.1136/bmjopen-2018-027083
Open access 
for 2–4 weeks.6 Previous studies have shown that 2 weeks of 
oral doxycycline and intravenous ceftriaxone are equally 
effective for LNB with painful radiculitis or cranial neuritis 
and probably also for LNB with symptoms from the central 
nervous system (myelitis and encephalitis).7–9 Arguments 
for choosing oral doxycycline are that it is inexpensive and 
convenient, is found to penetrate the blood–brain barrier 
and give adequate concentrations in the CSF and is effec-
tive against coinfections with other tick-borne agents.10 11
We lack evidence about the optimal duration of antibi-
otic treatment. Most guidelines recommend treatment for 
14–28 days.6 12 13 In Norway, the site for the current study, 
the guidelines recommend 14 days of treatment. A recent 
Cochrane review of six randomised treatment studies of 
adult patients with acute LNB reported improvement in 
the majority of patients after the initial course of antibi-
otics and no consistent evidence of treatment failure or 
need of retreatment.14 In another systematic review, the 
authors conclude that there is insufficient evidence to 
determine if extended antibiotic treatment is beneficial to 
outcome.15 Despite this, and perhaps because of uncertain-
ties surrounding LNB, there are varying treatment regimes 
in clinical practice, generally with more extensive treat-
ment strategies than recommended in current guidelines. 
A recent study of the treatment practice of 253 Norwegian 
LNB patients showed that adherence to guidelines was poor 
and that two-thirds of the patients received >2 weeks of anti-
biotic treatment.16 In a time with increasing knowledge and 
awareness of microbial resistance and other complications 
of long-term antibiotic treatment, these findings seem like 
a paradox. The present study therefore seeks to increase 
the evidence of the current treatment advice by evaluating 
if treatment with doxycycline for 14 days is inferior or not 
to treatment for 6 weeks with respect to long-term prognosis 
of LNB.
MEthod
study design and interventions
The study is a randomised, double-blinded, placebo-con-
trolled, multicentre trial with a non-inferiority design. 
We plan to recruit 120 patients diagnosed with defi-
nite or probable LNB according to EFNS guidelines6 at 
six different hospitals in the southern part of Norway 
as shown in figure 1. The study is coordinated from 
Sørlandet Hospital in Kristiansand, Agder County by 
neurologists connected to the large BorrSci study (Lyme 
borreliosis; a scientific approach to reduce diagnostic and 
therapeutic uncertainties). The inclusion and exclusion 
criteria are shown in box 1. Inclusion started in 2015 and 
will continue through December 2019 or until the neces-
sary sample size is obtained. Eligibility before inclusion 
is assessed by, or discussed with, a physician connected 
to the study and accustomed to evaluating patients with 
neurological symptoms. The patients are randomised 
into two treatment arms: (A) doxycycline 200 mg daily for 
2 weeks, followed by 4 weeks of placebo; (B) doxycycline 
200 mg daily for 6 weeks (figure 2).
Allocation and blinding
Computerised allocation (stratified according to hospital) 
is performed at Department of Clinical Research Support, 
Oslo University Hospital, by an internet-based solution. 
Maximum objective performance and reporting of the 
study is achieved by applying a ‘penta-blinded’ approach. 
The first and second blinding is the traditional double 
blind design with blinding of participants and investiga-
tors. Third, the staff evaluating endpoints and adverse 
effects is blinded to all other study information. Further, 
the content of all tables and figures will be fixed before 
any study data are available. Lastly, the statistical proce-
dures will be performed with the two treatment arms 
marked as group A and B. Revealing the study arms for 
the investigators will not take place until all patients have 
completed the 6-month visit, and for the patients after 
the 12-month visit.
Monitoring and data collection
The study is monitored independently according to good 
clinical practice (GCP) by the Department of Clinical 
Figure 1 Map of Norway with the active centres of 
recruitment per August 2018 marked in red.
box 1 Inclusion and exclusion criteria
Inclusion criteria
1. Neurological symptoms suggestive of Lyme neuroborreliosis with-
out other obvious reasons, and one or both of
a. CSF pleocytosis (leucocytes ≥5/mm3).
b. Intrathecal Borrelia burgdorferi antibody production.
2. Signed informed consent.
Exclusion criteria
1. Age <18 years.
2. Treatment with cephalosporin, penicillin  or tetracycline macrolide 
during the last 14 days before start of doxycycline treatment.
3. Pregnancy, breast  feeding and/or women of childbearing potential 
not using adequate contraception.
4. Adverse reaction to tetracyclines.
5. Serious liver or kidney disease that contraindicates use of doxycyline.
6. Lactose intolerance.
7. Need to use medications contraindicated according to summary 
of product characteristics (SmPC) of the Investigational Medicinal 
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Research. The coordinating investigators at Sørlandet 
Hospital and investigators at cooperating centres are 
certified according to GCP. The investigators will enter 
the data required by protocol into an electronic Case 
Report Form (Viedoc), also designed by the Department 
of Clinical Research. The same protocol for data manage-
ment and monitoring is applied to all collected data.
outcome measures
A composite clinical score (CCS) based on subjective 
symptoms and objective neurological findings from the 
peripheral and central nervous system (box 2) is regis-
tered at baseline, 10 weeks, 6 months and 12 months. 
Each of the 32 items of the CCS is scored 0=none, 1=mild 
(without influence on daily life) or 2=severe (with influ-
ence on daily life). Maximum total score is 64. The 
primary endpoint of the study is the difference in CCS 
sum score at baseline and 6 months after inclusion.
Secondary endpoints are the difference in CCS 
at baseline and 12 months after inclusion, fatigue 
scored according to the questionnaire Fatigue Severity 
Scale (FSS) at 6 and 12 months, subjective somatic 
symptoms scores according to the Patient Health Ques-
tionnaire (PHQ)-15 at 6 and 12 months and health-re-
lated quality of life according to RAND 36-item short 
form health survey at 6 months, and side effects of the 
treatment.
 FSS measures level of agreement from 1 to 7 points 
with nine statements with the final score representing the 
mean value of nine items. FSS scores≥5 are regarded as 
severe fatigue. The FSS has been translated into Norwe-
gian, validated in the general Norwegian population and 
normative Norwegian data are available.17
PHQ-15 charts prevalence and intensity of 13 somatic 
symptoms; fatigue/lack of energy and difficulty sleeping 
during the last 4 weeks. Sum score ranges from 0 to 28 
for men and from 0 to 30 for women (only women are 
asked about menstrual symptoms). The following cut-off 
values for sum score have been stated for load of somatic 
symptom, 0–4 points: normal, 5–9 points: mild, 10–14 
points: moderate, 15–30 points: severe. The PHQ-15 
has been validated in several studies and languages, and 
normative Swedish data are available.18
RAND 36-item short form health survey consists of 36 
questions about different aspects of health-related quality 
of life. The answer to each question is transformed into a 
score ranging from 0 to 100, where a higher score indicates 
Figure 2 Inclusion procedures. LNB, Lyme neuroborreliosis.  
box 2 Composite clinical score





 ► Neck and/or back pain.
 ► Abdominal and/or breast pain.
 ► Arm pain.
 ► Leg pain.
 ► Generalised pain located to joints and/or muscles.
 ► Memory and/or concentration problems.
 ► Other.
Peripheral findings related to the current Lnb:
 ► Facial palsy.
 ► Paresis of the eye muscles.
 ► Reduced hearing.
 ► Other cranial neuropathies.
 ► Cervical radicular sensory findings.*
 ► Cervical radicular paresis.† 
 ► Thoracic radicular sensory findings.*
 ► Lumbar radicular sensory findings.*
 ► Lumbar radicular paresis.† 
 ► Non-radicular sensory findings.‡ 
 ► Non-radicular paresis.§ 
 ► Other.
Central findings related to the current Lnb:
 ► Central findings in one extremity.¶
 ► Central findings in a hemi pattern.
 ► Central findings in both legs.
 ► Central findings in all extremities.
 ► Gait ataxia.
 ► Dysphasia/aphasia.
 ► Nystagmus.
 ► Involuntary movement including tremor.
 ► Cognitive impairment.
 ► Other.
*Abnormal sensory pattern in a radicular pattern. 
†Paresis in a radicular pattern. 
‡Sensory findings matching with a peripheral nerve or plexus. 
§Paresis matching a peripheral nerve or plexus.
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better health. The questionnaire is validated in Norwe-
gian, and Norwegian normative data are available.19
Thee patient reported outcome measures were 
included as secondary endpoints to evaluate the potential 
impact of residual symptoms on patients daily life.
Systemic and CSF inflammation will be assessed with 
lumbar punctures and blood samples at 6 and 12 months 
after treatment. There will be established a biobank from 
this material. Figure 3 depicts a flowchart of the study 
procedures.
safety
The patients are followed closely during and after treat-
ment to monitor safety. They are contacted by phone 
1 week after start of treatment and questioned about 
symptom severity and possible side effects. Blood sampling 
with a status of haematology, liver and kidney function to 
monitor potential side effects takes place at 2 and 4 weeks 
after start of treatment. The patients are also asked to fill 
out a patient diary on symptoms and possible side effects 
once a week for 10 weeks.
In cases of disease progression, the patients will be eval-
uated by a physician and adequate intervention initiated. 
Disease progression is, in this trial, defined as worsening 
of the patient’s condition attributed to LNB, despite treat-
ment for 14 days with doxycycline, or serious progression 
of neurological signs from CNS during treatment.
sample size
We used data including the SD from our previous treat-
ment trial on 102 LNB patients treated with either oral 
doxycyline or intravenous cephtriaxone for 2 weeks and 
scored with an almost similar clinical scale as the CCS in 
the power analyses.7
From a clinical point of view, a mean group difference 
of Δ=0.5 in disfavour of 2 weeks treatment compared 
with 6 weeks treatment was regarded as an appropriate 
non-inferiority margin. This non-inferiority margin corre-
sponds to a Cohen's d effect size of Δ/σ=0.5/1.0=0.5, 
which is a small and clinical acceptable effect size. With 
a one-sided test and significance level of 0.05, 50 patients 
in each treatment group was found to be needed to claim 
non-inferiority with a non-inferiority margin on mean 
group difference of 0.5 and a SD of 1.0 with 80% power. 
To compensate for up to 20% dropouts and non-evalu-
able patients 120 (ie, 60 in each group) patients will be 
enrolled.
statistical analysis
The main statistical analysis is planned when all patients 
have completed the 6-month visit. Results will be reported 
as mean scores with SD or proportions as appropriate.
To compare the primary outcome in the two groups we 
will use a general linear model with treatment group as a 
factor, and adjustment for duration of symptoms, gender 
and age. The analysis will be conducted according to the 
intention-to-treat principle.
For other analysis, comparison between groups will 
be done with, for example, independent samples t-test, 
non-parametric Mann-Whitney U test or Pearson’s χ2 test 
for crosstabs as appropriate. Results from the FSS and 
PHQ-15 questionnaires will be dichotomised according 
to predefined cut-offs recommended for case definition 
and statistically treated as categorical outcomes.
P values <0.05 will be considered statistically significant.
Ethics and dissemination
The trial is registered on  Clinicaltrials. org. The study will 
be conducted in accordance with ethical principles that 
have their origin in the Declaration of Helsinki and are 
consistent with Internation Conference of Harmonisa-
tion- Good Clinical Pratice (ICH/GCP) (and applicable 
regulatory requirements.
Each patient in the trial is submitted to extensive 
follow-up as previously described in terms of disease, 
effect of treatment and side effects to outweigh poten-
tial harms. The benefits are considered to outweigh the 
cons of this trial in the long term, with a potentially more 
evidence-based treatment of LNB and less extensive use 
of antibiotics.
Data from the study will be published in peer-reviewed 
medical journals.
Patient and public involvement
Representatives from the Norwegian patient organisation 
for Lyme borreliosis (Norsk Lyme Borreliose Forening) 
were invited and participated in the early stages of plan-
ning of the BorrSci project’s design and gave feedback on 
the drafts of the application for funding. They were also 
invited to continue work with the project. Inclusion to the 
study, implications of the intervention and time required 
to participate is discussed with each individual patient. 
Local newspapers and other media have been involved in 
making the project known to the public in different parts 
of Norway. 
Contributors AMS contributed in drafting this manuscript, has participated in 
revisions of the original protocol, includes patients to the study and coordinates 
the study at Sørlandet Hospital and at the other centres of recruitment. UL and ÅM 
Figure 3 Flowchart of the study procedures. FSS, Fatigue 
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